Stocktoria
Aspire Biopharma Holdings, Inc. ASBP
Aspire Biopharma Holdings, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $6,202 | — | — | — |
| Gross profit | -$116 | — | — | — |
| R&D expense | $923,914 | $144,356 | — | — |
| Operating income | -$19.4M | -$1.2M | — | — |
| Income tax | — | $1,013 | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | $3.3M |
| EPS (diluted) | $-16.38 | $-1.90 | — | — |
| Operating cash flow | -$4.9M | -$265,186 | -$653,107 | -$1.4M |
| Cash & equivalents | $1.0M | — | — | — |
| Inventory | $253,160 | — | — | — |
| Total assets | $1.3M | $147,989 | $20.0M | $300.2M |
| Total liabilities | $7.7M | $1.7M | $403,328 | $11.1M |
| Shareholders' equity | -$6.4M | -$1.5M | -$487,861 | -$9.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net income growth | — | -129.3% | +33.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.